Figure 3.
Figure 3. Detection of preleukemic clones in mobilized PBSCs. The presence of preleukemic mutations was determined in PBSC material of 10 patients for whom mutational data were available at the time point of tMN diagnosis. Preleukemic clones could be determined in 7 of 10 analyzed cases at indicated VAFs. Panels A-D were analyzed by a myeloid gene panel, and panels E-G were analyzed by WES. In patients UPN02, UPN12, UPN15, UPN20, and UPN18 (A-E), a mutation present in the leukemic clone could be detected in PBSCs, whereas the detected variant in the PBSCs of patient UPN13 represents a bystander clone (G). For patient UPN03 (F), mutations that represent both a leukemic and bystander clone were detected in PBSCs.

Detection of preleukemic clones in mobilized PBSCs. The presence of preleukemic mutations was determined in PBSC material of 10 patients for whom mutational data were available at the time point of tMN diagnosis. Preleukemic clones could be determined in 7 of 10 analyzed cases at indicated VAFs. Panels A-D were analyzed by a myeloid gene panel, and panels E-G were analyzed by WES. In patients UPN02, UPN12, UPN15, UPN20, and UPN18 (A-E), a mutation present in the leukemic clone could be detected in PBSCs, whereas the detected variant in the PBSCs of patient UPN13 represents a bystander clone (G). For patient UPN03 (F), mutations that represent both a leukemic and bystander clone were detected in PBSCs.

Close Modal

or Create an Account

Close Modal
Close Modal